Login / Signup

KLRG1, Another Opportunity for a Breakthrough in MTCL.

Gaurav VarmaCatherine S Diefenbach
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Outcomes in mature T-cell lymphomas remain poor, with previous attempts at developing monoclonal antibodies (mAb) compromised by limited efficacy and significant immunocompromise. Anti-killer cell lectin-like receptor G1 mAbs may have greater selectivity and specificity for malignant T-cells and avoid the toxicity concerns with previous agents.
Keyphrases
  • single cell
  • cell therapy
  • oxidative stress
  • structural basis
  • stem cells
  • type diabetes
  • metabolic syndrome
  • mesenchymal stem cells
  • low density lipoprotein